{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T22:44:00Z","timestamp":1759099440725,"version":"3.41.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2002,9,1]],"date-time":"2002-09-01T00:00:00Z","timestamp":1030838400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2002,9,1]],"date-time":"2002-09-01T00:00:00Z","timestamp":1030838400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"published-print":{"date-parts":[[2002,9]]},"DOI":"10.1023\/a:1022194604260","type":"journal-article","created":{"date-parts":[[2003,3,22]],"date-time":"2003-03-22T00:29:05Z","timestamp":1048292945000},"page":"451-456","source":"Crossref","is-referenced-by-count":10,"title":["Use of Cardiovascular Drugs After Acute Myocardial Infarction: A Marked Shift Towards Evidence-Based Drug Therapy"],"prefix":"10.1007","volume":"16","author":[{"given":"\u00c5smund","family":"Reikvam","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Kvan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivar","family":"Aursnes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"5114393_CR1","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(96)90732-1","volume":"347","author":"The European Secondary Prevention Study Group.","year":"1996","unstructured":"The European Secondary Prevention Study Group. Translation of clinical trials into practice: A European population based study of the use of thrombolysis for acute myocardial infarction. Lancet 1996;347:1203\u20131207.","journal-title":"Lancet"},{"key":"5114393_CR2","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1046\/j.1365-2796.1998.00288.x","volume":"243","author":"A Reikvam","year":"1998","unstructured":"Reikvam A, Abdelnoor M, Sivertssen E. For the European Secondary Prevention Study Group. Has hospital mortality from acute myocardial infarction been markedly reduced since the introduction of thrombolytics and aspirin? J Intern Med 1998;243:259\u2013263.","journal-title":"J Intern Med"},{"key":"5114393_CR3","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S0895-4356(99)00042-6","volume":"52","author":"A Reikvam","year":"1999","unstructured":"Reikvam A, Aursnes I. For the European Secondary Prevention Study Group. Hospital mortality from acute myocardial infarction has been modestly reduced after introduction of thrombolytics and aspirin: Results from a new analytical approach. J Clin Epidemiol 1999;52:609\u2013613.","journal-title":"J Clin Epidemiol"},{"key":"5114393_CR4","first-page":"1671","volume":"116","author":"A. Reikvam","year":"1996","unstructured":"Reikvam A. Use of thrombolytic agents and other drugs in acute myocardial infarction. Tidsskr Nor Laegeforen 1996;116:1671\u20131674.","journal-title":"Tidsskr Nor Laegeforen"},{"key":"5114393_CR5","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1053\/euhj.1997.0560","volume":"19","author":"KL Woods","year":"1998","unstructured":"Woods KL, Ketley D, Lowy A, et al. Beta-blockers and antithrombotic treatment for secondary prevention after acute myocardial infarction. Eur Heart J 1998;19:74\u201379.","journal-title":"Eur Heart J"},{"issue":"Suppl.1","key":"5114393_CR6","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.1016\/S0021-9150(99)00254-3","volume":"147","author":"JA. Velasco","year":"1999","unstructured":"Velasco JA. After 4S, CARE and LIPID-is evidence-based medicine being practised? Atherosclerosis 1999;147(Suppl. 1):S39\u2013S44.","journal-title":"Atherosclerosis"},{"key":"5114393_CR7","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s002280050446","volume":"54","author":"M Martinez","year":"1998","unstructured":"Martinez M, Augusti A, Arnau JM, Vidal X, Laporte JR. Trends of prescribing patterns for the secondary prevention of myocardial infarction over a 13-year period. Eur J Clin Pharmacol 1998;54:203\u2013208.","journal-title":"Eur J Clin Pharmacol"},{"key":"5114393_CR8","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1093\/oxfordjournals.eurheartj.a060388","volume":"15","author":"K Py\u00f6r\u00e4l\u00e4","year":"1994","unstructured":"Py\u00f6r\u00e4l\u00e4 K, De Backer G, Graham I, Poole-Wilson P, Wood D. Prevention of coronary heart disease in clinical practice: Recommendations of the task force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. Eur Heart J 1994;15:1300\u20131331.","journal-title":"Eur Heart J"},{"key":"5114393_CR9","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1053\/euhj.1998.1243","volume":"19","author":"D Wood","year":"1998","unstructured":"Wood D, de Backer G, Faergeman O, Graham I, Mancia G, Py\u00f6r\u00e4l\u00e4 K. Prevention of coronary heart disease in clinical practice: Recommendations of the Second Joint Task Force of European and other societies on coronary prevention. Eur Heart J 1998;19:1434\u20131503.","journal-title":"Eur Heart J"},{"key":"5114393_CR10","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1016\/S0735-1097(96)00392-0","volume":"28","author":"TJ Ryan","year":"1996","unstructured":"Ryan TJ, Anderson JL, Antman EM, et al.ACC\/AHAguidelines for the management of patients with acute myocardial infarction: A report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 1996;28:1328\u20131428.","journal-title":"J Am Coll Cardiol"},{"key":"5114393_CR11","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1080\/14017430260180373","volume":"36","author":"A Reikvam","year":"2002","unstructured":"Reikvam A, Hagen T. Markedly changed age distribution among patients hospitalized for acute myocardial infarction. Scand Cardiovasc J 2002;36:221\u2013224.","journal-title":"Scand Cardiovasc J"},{"key":"5114393_CR12","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJM200001203420301","volume":"342","author":"S Yusuf","year":"2000","unstructured":"Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342:145\u201353.","journal-title":"N Engl J Med"},{"key":"5114393_CR13","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1093\/oxfordjournals.eurheartj.a015136","volume":"18","author":"EUROASPIRE Study Group.","year":"1997","unstructured":"EUROASPIRE Study Group. EUROASPIRE: A European Society of Cardiology survey of secondary prevention of coronary heart disease: Principal results. Eur Heart J 1997;18:1569\u20131582.","journal-title":"Eur Heart J"},{"key":"5114393_CR14","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/S0140-6736(00)04235-5","volume":"357","author":"EUROASPIRE III Group.","year":"2001","unstructured":"EUROASPIRE I and II Group. Clinical reality of coronary prevention guidelines: A comparison of EUROASPIRE I and II in nine countries. Lancet 2001;357:995\u20131001.","journal-title":"Lancet"},{"key":"5114393_CR15","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/S0300-8932(97)73242-1","volume":"50","author":"JA de Velasco","year":"1997","unstructured":"de Velasco JA, Cosin J, Lopez Sendon JL, et al. Secondary prevention of myocardial infarction in Spain. The PREVERSE study. Rev Esp Cardiol 1997;50:406\u2013415.","journal-title":"Rev Esp Cardiol"},{"key":"5114393_CR16","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0021-9150(00)80483-9","volume":"151","author":"M de Oya","year":"2000","unstructured":"de Oya M, Lopez-Sendon JL, de Teresa E, et al. On behalf of PREVESE 98 Study Group. The impact of landmark clinical trials on secondary prevention of acute myocardial infarction (AMI) in Spain. Prevese 98 study (Abstr). Atherosclerosis 2000;151:107.","journal-title":"Atherosclerosis"},{"key":"5114393_CR17","first-page":"349","volume":"2","author":"Second International Study of Infarct Survival","year":"1988","unstructured":"Second International Study of Infarct Survival (ISIS-2) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988;2:349\u2013360.","journal-title":"Lancet"},{"key":"5114393_CR18","first-page":"1383","volume":"344","author":"4S Investigators.","year":"1994","unstructured":"4S Investigators. Randomized trial of cholesterol lowering in 4,444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383\u20131389.","journal-title":"Lancet"},{"key":"5114393_CR19","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1001\/jama.283.10.1295","volume":"283","author":"A Hjalmarson","year":"2000","unstructured":"Hjalmarson A, Goldstein S, Fagerberg B, et al. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: The Metoprolol CR\/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group. JAMA 2000;283:1295\u20131302.","journal-title":"JAMA"},{"key":"5114393_CR20","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/S0140-6736(99)11180-2","volume":"355","author":"K Kuulasmaa","year":"2000","unstructured":"Kuulasmaa K, Tunstall-Pedoe H, Dobson A, et al. Estimation of contribution of changes in classic risk factors to trends in coronary-event rates across the WHO MONICA Project populations. Lancet 2000;355:675\u2013687.","journal-title":"Lancet"},{"key":"5114393_CR21","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/S0140-6736(99)11181-4","volume":"355","author":"H Tunstall-Pedoe","year":"2000","unstructured":"Tunstall-Pedoe H, Vanuzzo D, Hobbs M, et al. Estimation of contribution of changes in coronary care to improving survival, event rates, and coronary heart disease mortality across the WHO MONICA Project populations. Lancet 2000;355:688\u2013700.","journal-title":"Lancet"}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1023\/A:1022194604260.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1023\/A:1022194604260\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1023\/A:1022194604260.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T19:05:34Z","timestamp":1751051134000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1023\/A:1022194604260"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,9]]},"references-count":21,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2002,9]]}},"alternative-id":["5114393"],"URL":"https:\/\/doi.org\/10.1023\/a:1022194604260","relation":{},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"type":"print","value":"0920-3206"},{"type":"electronic","value":"1573-7241"}],"subject":[],"published":{"date-parts":[[2002,9]]}}}